ASML Q3 2026 Earnings: €4.96B Profit on Record €11.7B Sales as Demand Outruns Supply Into 2028

On October 14, 2026, ASML reported third-quarter total net sales of €11,662 million, up 55.2% year-over-year, at a 57.5% gross margin, with net income of €4,960 million — a 42.5% net margin — and guided full-year sales to €44–45 billion. Then management said the quiet part out loud: planned supply for 2027 and 2028 will not meet customer demand. The shares still slipped about 3% on a narrow revenue miss. This is the EUV monopoly hitting the physical limits of its own output.

The Headline Numbers​

ASML Holding N.V.'s fiscal year is the calendar year; Q3 2026 is the three months ended September 27, 2026. The company reports under US GAAP in euros, and nothing here is converted. Every figure below comes from the Q3 2026 press release and the summary US GAAP financial statements furnished as exhibits to the October 14 Form 6-K.

Revenue grew 55% while cost of sales grew 36%, so gross profit grew 73% — the entire quarter in one sentence. Below that, two things compound the beat into a 134% net-income print. First, operating leverage is extreme: R&D rose just 5.9% against 55% sales growth, so operating income more than doubled and operating margin expanded nearly 12 points to 44.4%. Second, a €509.7 million fair-value gain on equity investments — the Mistral AI stake, marked up — added roughly a tenth of net income before tax. Strip it out and this is still a record quarter; leave it in and the 42.5% net margin flatters the operating story by about four points.

The effective tax rate fell to 16.1% from 17.8%, and the share count keeps shrinking — 383.1 million basic shares against 387.3 million a year ago — so EPS grew slightly faster than net income. Sequentially the acceleration is just as stark: sales up 25.0% and net income up 70.0% from Q2, with gross margin up 3.5 points to 57.5%.

Revenue Deep Dive​

ASML sells two things — new machines and everything around the machines already installed — and this quarter both fired, with the steadier one growing faster.

Systems revenue of €8,373 million on 121 tools implies roughly €69 million per system, down from about €77 million a year ago — an approximation, since system sales include metrology tools the unit count excludes, but the direction says mix shifted toward lower-value DUV tools even as EUV demand dominates the narrative. Management's demand language is unusually blunt: "Our customers continue to increase their short- and medium-term equipment demand forecasts with us, driven primarily by their views on the size and duration of AI-related investments." And then the line that matters most for 2027: "some customers are expressing an interest in placing orders with us for 2029 and even 2030."

Installed Base Management — service and field options, the razor-blade half — grew 68% to €3,289 million, beating guidance. CEO Christophe Fouquet attributed it to "the continued strong demand for productivity upgrades," and added that IBM strength "drove the gross margin above guidance." When customers cannot buy enough new tools, they pay to squeeze more wafers out of old ones; IBM is where shortage demand shows up first.

One disclosure went missing. A year ago ASML reported quarterly net bookings of €5.4 billion, of which €3.6 billion EUV. This release reports no bookings figure at all — order-book momentum is described ("continues to increase quarter on quarter this year") but not quantified. The balance sheet fills part of the gap: non-current contract liabilities — customer down payments for future tools — nearly tripled to €9,301 million (more below). The demand is real and prepaid; the exact backlog number is not.

The Margin Story​

Five points of gross-margin expansion in one year has a mechanical explanation, and management gave it: mix. IBM sales carry software-like margins relative to hardware, and IBM grew 68% against 51% for systems. The release guides Q4 gross margin "around 57%" and the full year "around 56%" — management is telling you this quarter's mix is roughly the new run rate, not a one-off.

Operating margin did something rarer, jumping from 32.8% to 44.4%. The mechanics: cost of sales grew slower than revenue (mix again), R&D barely grew at all, and SG&A — up 16% — is barely 3% of sales. ASML's R&D line is essentially fixed in the short run against lithography demand that moves in steps, so every boom quarter drops disproportionately to operating income. The release contains no explicit selling-price language — no "pricing momentum," no ASP commentary — which is itself a signal: this margin expansion is volume and mix, not price increases. With customers begging for 2029 slots, ASML is rationing by queue, not by price.

Net margin's extra four points over operating come from below the line: the €509.7 million investment gain plus a lower tax rate. That is the part of the 42.5% that does not annualize cleanly.

The One Big Question: Can ASML Build Enough?​

Every number in this quarter is downstream of one constraint: ASML cannot make tools fast enough. "We now expect that our supply as currently planned for both 2027 and 2028 will not fully meet the demand of our customers," Fouquet said — as direct a sold-out-two-years-forward statement as a public company ever makes. The release frames the response in stages: a 30% increase in low-NA EUV and DUV immersion capacity planned for 2027, and now an investigation into raising 2028 capacity "beyond the 30% increase we previously communicated."

The balance sheet confirms the deal flow is already funded. Non-current contract liabilities stand at €9,301 million, up from €3,366 million at the end of 2025 — customers wiring money years ahead of delivery. Total contract liabilities were €19,373 million at year-end 2025; the Q3 release folds the current portion into one aggregate line, but the non-current tripling alone is the order book speaking. Meanwhile receivables tripled to €9,253 million from €3,023 million at year-end as recognized revenue outran collections — nothing is piling up in inventory (flat at €11.9 billion), everything is piling up in "ship it faster."

The peer comparison sharpens the picture. TSMC — ASML's largest customer and the company buying most of these EUV tools — just reported HPC at 68% of its own revenue and is pulling Arizona fab capacity forward. Read the two ledgers together and the chain is unbroken: AI datacenter demand → TSMC leading-edge orders → ASML tools sold out into 2028. The risk sits at the top of that chain, not the bottom: if AI capex pauses, ASML's backlog is cancellation-protected by contract penalties but its 2029 "interest" is not yet orders.

(Receivables and inventories are as filed; contract liabilities are the non-current caption the summary balance sheet prints separately.)

What Wall Street Thinks​

Record numbers, raised guidance — and the stock fell. Coverage attributed the slip of around 3% in early trading to a narrow top-line miss: €11.66 billion converted to roughly $13.07 billion against about $13.12 billion of consensus, with profit beating by a wide margin and the full-year outlook raised; a second account has the shares down as much as 3.6% intraday amid a broader tech selloff. The takeaway writes itself: at this valuation, "record" is the baseline and the quarter is graded against expectations, not history. Analyst desks split the usual way afterward — Bank of America trimming its target while Citi and Barclays raised theirs — but the price action, not the notes, is the signal: the market is no longer asking whether ASML can grow, only how fast.

Tracking a €59 Billion Company in Plain Text​

A company this cyclical deserves double-entry: every euro of that €59 billion balance sheet has to reconcile, and Beancount forces it to. Our open-ledger conventions model every company the same way — one zero-sum income transaction per period, balance-sheet assertions against the filing — so ASML reads directly beside the TSMC ledger published the same week.

; Check: −11,662.0 + 4,962.2 + 1,174.4 + 352.6 − 509.7 − 68.2 − 134.7 + 925.0 + 4,960.4 = 0 ✓
2026-09-27 * "ASML Holding N.V." "FY2026Q3 Income Statement"
  Income:Revenue                         -11662.0 MEUR
  Expenses:CostOfRevenue                   4962.2 MEUR
  Expenses:ResearchAndDevelopment          1174.4 MEUR
  Expenses:SellingGeneralAdministrative     352.6 MEUR
  Income:OtherNet                          -509.7 MEUR
  Income:OtherNet                           -68.2 MEUR
  Income:OtherNet                          -134.7 MEUR
  Expenses:IncomeTax                        925.0 MEUR
  Equity:Adjustments                       4960.4 MEUR

Income posts negative (credit), expenses positive (debit), and the Equity:Adjustments line absorbs net income so the transaction sums to zero — the check comment above it is the proof. Below the operating line, the three Income:OtherNet postings are the quarter's whole below-the-line story in labeled form: the €509.7 million Mistral-markup gain, €68.2 million of interest and other, and the €134.7 million Zeiss equity-method profit.

The one balance-sheet number that tells the narrative is non-current contract liabilities: €3,366 million at the end of 2025, €9,301 million nine months later. That is prepaid demand, and it is why "sold out into 2028" is an accounting fact before it is a CEO quote.

The Multi-Year Arc​

(Cash returned is dividends paid plus treasury-share purchases from each year's cash-flow statement; Q3 2026 is the quarter's €721.3 million of dividends plus €4,071.0 million of buybacks.)

The arc is a monopoly compounding through cycles. Revenue nearly doubled from FY2021 to FY2025 while R&D held a steady 14–15% of sales — ASML spends like a research lab with a toll booth attached. Gross margin hovered just above 50% for five straight years, then jumped five points in nine months on IBM mix. And the capital return is relentless: €32 billion handed back over five years, with a fresh 2026–2028 buyback program under which Q3 alone repurchased €4.1 billion across some 2.8 million shares. The share count fell from 409.8 million (FY2021 basic weighted average) to 383.1 million this quarter — 6.5% of the company retired while revenue doubled.

The Verdict: Bull vs. Bear​

Bull Case

• Two years of visibility, prepaid. Non-current contract liabilities nearly tripled to €9.3 billion, and customers are asking about 2029–2030 slots. This is demand you can audit, not guidance you have to trust.
• The margin step looks structural. IBM at 28% of sales and growing 68% is a mix shift toward the highest-margin revenue, and management guides ~56–57% gross margin forward, not back down to 52%.
• Operating leverage is only starting. R&D at 10.1% of quarterly sales against a 14–15% annual norm means every incremental euro of 2027–2028 output drops disproportionately to operating income.
• Capital return accelerates into strength. €4.8 billion returned in a single quarter, a growing dividend (€1.88 interim, second €1.88 payable November 4), and buybacks compounding EPS at 136% growth.
• High-NA is the next toll. The TSMC joint initiative on 12-inch photomasks for High-NA EUV — promising over 40% productivity gains — extends the moat into the next decade just as leading-edge demand broadens.

Bear Case

• The quarter flatters itself. €509.7 million of the €4,960 million net income is an unrealized markup on the Mistral stake, and the 16.1% tax rate sits below the guided ~17%. Underlying operating momentum is real but the 42.5% net margin is not the run rate.
• Booked is not ordered. The release stopped quantifying net bookings even as it talks up momentum, and 2029–2030 "interest" carries no penalties until it becomes authorized orders. The backlog trough of 2023–2024 (contract liabilities fell two years running) is the template for how fast this reverses.
• China is the known hole. A year ago management warned China demand in 2026 would "decline significantly" from very strong 2024–2025 levels; this release says nothing about China at all. Silence plus export controls equals downside nobody is modeling.
• Capacity bets cut both ways. A 30%-plus capacity expansion into 2027–2028 is fixed cost against AI-capex forecasts that have never survived a downturn intact. If customers' "views on the size and duration of AI investments" shorten, ASML owns the fabs.
• Priced for the beat. The stock fell on a record quarter over a 0.4% revenue miss. Expectations now assume flawless execution into a sold-out 2028 — any slip in EUV output, yields, or High-NA adoption reprices the shares against a perfect quarter they already shrugged at.

Our Take

Buy the constraint, not the quarter. ASML just told you — in filed numbers, not adjectives — that the world's most important machines are sold out for two years, that customers are prepaying billions for 2029 tools that do not exist yet, and that the highest-margin half of the business is growing fastest. The market's shrug is short-term arithmetic meeting long-term physics: lithography is the narrowest choke point in the AI build-out, and choke points get paid. The risks are real — China, cyclicality, a valuation that grades on perfection — but they are risks around timing, not around whether the toll gets collected. This is the company.